All-trans retinoic acid (ATRA) induces differentiation of NB4 and HL-60 leukemia cells, but not R4 and HL-60/Res cells. Three agents used in cancer therapy, doxorubicin (Dox), arsenic trioxide (As 2 O 3 ) and paclitaxel, induce apoptosis, but not differentiation, in all of these cell lines. The induction of apoptosis by these agents is decreased in ATRA-pretreated NB4 and HL-60 cells, but not in ATRA-pretreated R4 and HL-60/ Res cells. The level of Bcl-2 protein is decreased by ATRA treatment in NB4, HL-60 and HL-60/Res cells. The level of Mcl-1 protein is increased by ATRA treatment in NB4 and R4 cells, but not in HL-60 and HL-60/Res cells. Bfl-1/A1 mRNA is not expressed in these cell lines, however, its expression is markedly induced by ATRA treatment in NB4 and HL-60 cells, but not in R4 or HL-60/Res cells, which correlates with inhibition of apoptosis. Inhibiting Bfl-1/A1 mRNA upregulation in ATRA-pretreated NB4 cells using small interfering RNA (siRNA) partly recovers cell sensitivity to Dox-induced apoptosis. These data demonstrate that ATRA induction of Bfl-1/A1 in differentiated NB4 and HL-60 cells contributes to a loss of sensitivity to chemotherapy-induced apoptosis.
Introduction
The combination of all-trans retinoic acid (ATRA) treatment, a differentiation inducer, with chemotherapy (mainly anthracyclines) achieves 85% long-term survival rate in acute promyelocytic leukemia (APL) patients. The therapeutic effect of this combination is significantly superior to ATRA or chemotherapy alone. [1] [2] [3] [4] [5] Most APL patients that relapse and become resistant to ATRA plus chemotherapy respond to subsequent arsenic trioxide (As 2 O 3 ) treatment with disease remission. [6] [7] [8] Recently it has been shown that the combination treatment of ATRA with As 2 O 3 has improved therapeutic outcome in APL patients than using either agent alone. 9, 10 All-trans retinoic acid, anthracyclines and As 2 O 3 appear to induce non-cross resistant clinical remission through different mechanisms (differentiation and/or apoptosis), therefore using combinations of ATRA with an anthracycline or As 2 O 3 should have an advantage over single agent therapy. However, schedule-dependent synergism and antagonism of differentiation and apoptosis have been observed with different combinations of these agents. [11] [12] [13] [14] On the processes of differentiation and apoptosis induction in vitro, both synergistic and antagonistic effects have been reported when combining ATRA treatment with As 2 O 3 treatment of leukemia cells. [12] [13] [14] It has been found that some cancer cells become less sensitive to cytotoxic agent-induced apoptosis following agents that induce differentiation. [15] [16] [17] [18] [19] [20] These observations suggest that during the ATRA-induced differentiation process a cell death protection program is initiated that will attenuate the cytotoxic effect of chemotherapeutic agents.
Bcl-2 family members play important roles in the apoptosis process and their expression levels influence the induction of apoptosis by chemotherapeutic agents. 21, 22 Several members of Bcl-2 family such as Bcl-2 and Bfl-1/A1 have been found to be regulated by ATRA during the APL cell differentiation process. 14, 23, 24 Bfl-1/A1 has been found to be a potent antiapoptotic factor in myeloma and lymphoma. [25] [26] [27] By comparing ATRAsensitive NB4 (APL cells with t [15;17] ) 28 and HL-60 cells (derived from an APL-like patient without t [15;17] ) and their ATRA-resistant clones R4 29 and HL-60/Res, 30 respectively, we found that pretreatment of NB4 and HL-60 cells with ATRA decreased doxorubicin (Dox), As 2 O 3 and paclitaxel-induced cell death. The induction of Bfl-1/A1 was correlated with the attenuation of apoptosis in ATRA-treated NB4 and HL-60 cells. Silencing of Bfl-1/A1 using small interfering RNA (siRNA) partially restored sensitivity of ATRA-treated NB4 cells to Doxinduced apoptosis. These data suggest that increased expression of Bfl-1/A1 in leukemia cell undergoing differentiation has an important role in attenuating cytotoxic chemotherapeutic agentinduced apoptosis.
Materials and methods

Reagents
All-trans retinoic acid, paclitaxel, Dox, acridine orange (AO), ethidium bromide (EB) were purchased from Sigma Chemical Co. (St Louis, MO, USA 28 and an ATRA resistant derivative line, R4, was provided by Dr WH Miller Jr. 29 HL-60 and HL-60/Res cells were obtained from Dr R Gallagher. 30 The cells were cultured in RPMI-1640 medium supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, 1 mM L-glutamine and 10% fetal bovine serum. Cells in logarithmic growth were seeded at 1 Â 10 5 cells/ml. Studies were performed in duplicate and repeated at least three times.
The nitroblue tetrazolium (NBT) reduction assay was performed as previously reported. 14 
Quantitation of apoptotic cells
Apoptotic cells were assessed by fluorescence microscopy after staining with AO and EB 31 and by FACS after staining with annexin V-FITC. 32 For AO and EB staining, 1 ml of stock solution containing 100 mg/ml AO and 100 mg/ml EB was added to 25 ml of cell suspension. Total cells (300 of the cells will be counted) as well as the percentage of apoptotic cells which showed nuclear shrinkage, blebbing and apoptotic bodies, were determined. For annexin V staining assay, 10 6 cells were washed twice with phosphate-buffered saline then labeled by annexin V-FITC and propidium iodide (PI) in binding buffer according to the instructions in the annexin V-FITC Apoptosis Detection Kit provided by the manufacturer (Oncogene, Cambridge, MA, USA). The fluorescent signals of FITC and PI were detected at 518 nm and at 620 nm, respectively, on a FACScan (Becton Dickson, San Jose, CA, USA). The log of annexin-V-FITC fluorescence was displayed on the X axis and the log of PI fluorescence on the Y axis. The data were analyzed using the CELLQuest (Becton Dickson) program. For each analysis, 10 000 events were recorded Quantification of DNA fragmentation DNA fragmentation was quantified as described previously. 33 Cells were harvested by centrifugation, and cellular DNA was extracted with a PUREGENE DNA isolation kit (Gentra System, Minneapolis, MN, USA). Electrophoresis of 5 mg DNA was performed in 1% agarose gel in 40 mM Tris-acetate buffer (pH 7.4), at 50 V. After electrophoresis, DNA was visualized by EB staining.
Western blot analysis
Protein extracts (50 mg) prepared with RIPA lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 1% NP-40, 0.5% sodium deoxycholate, 1 mM phenylmethyl sulfonyl fluoride, 100 mM leupeptin and 2 mg/ml aprotinin, pH 8.0) were separated on an 8% SDS-polyacrylamide gel and transferred to nitrocellulose membranes. The membranes were stained with 0.2% Ponceau S red to assure equal protein loading and transfer. After blocking with 5% non-fat milk, the membranes were incubated with antibodies to Bcl-2 family members. 31 The immunocomplex was visualized by ECL Western Blotting Detection Reagents (Amersham Biosciences, England, UK).
Bfl-1/A1 small interfering RNA generation and transfection in NB4 cells Small interfering RNA preparation and transfection were performed according to the GTS kit instruction manual (San Diego, CA, USA). Template DNAs for transcription were prepared by polymerase chain reaction (PCR) with gene-specific PCR primers containing T7 RNA polymerase promoter site. The PCR primers (listed 5 0 -3 0 from Bcl-1/A1 sequence are underlined) were as follows: GCGTAATACGACTCACTATAGGGAGA ATGACAGACTGTGAATTTGGA ( þ 184/ þ 204) and GCGTAA TACGACTCACTATAGGGAGA TCAACAGTATTGCTTCAGGAG ( þ 691/ þ 711); 34 The PCR program used was 941C for 3 min followed by 35 cycles of 941C for 30 s, 581C for 30 s and 681C for 1 min and followed by 681C for 5 min. Double-stranded RNAs (dsRNAs) were produced by T7 transcription reaction using the PCR-amplified DNA template, and Dicer-siRNAs were generated using recombinant Dicer Enzyme and purified according to the manufacturer's instructions.
The GeneSilcencet Reagents and the d-siRNA were diluted by adding 3.5 ml or 10-25 ml serum-free medium, respectively. Those dilutions were mixed and incubated at room temperature for 5 min to allow for siRNA/lipid complex formation. NB4 cells treated with or without ATRA at 1 mM for 3 days were adjusted to 5 Â 10 5 with 0.5 ml serum-free medium in 24-well plates and the siRNA/GeneSilencert mix was gently added. The cells were cultured for 24 h followed by adding 1.5 ml complete medium, and were kept in culture for another 24 h. The morphology of the cells was monitored by microscopy and Bfl-1/A1 mRNA was tested by quantitative real-time (RT) PCR. The apoptotic response to 24 h Dox treatment was measured as described above.
Quantitative real-time polymerase chain reaction
Total RNA from NB4 cells treated with and without 1 mM ATRA for 3 days and transfected with d-siRNA (see above) for 2 days was extracted using the absolutely RNA RT-PCR Miniprep kit (Stratagene, La Jolla, CA, USA), which includes a DNase I treatment to avoid contamination by genomic DNA. Total RNA, 5 mg, was converted into cDNA using an oligo dT primer and 1/250 (approximately 500 pg DNA) was utilized for 40 cycle three-step PCR (after activation of the enzyme, 40 Â : 951C for 15 s, 551C for 15 s and 721C for 30 s). The quantitative real-time PCR was carried out using SYBR Green (Molecular Probes, Eugene, OR, USA) and Platinum Taq (Invitrogen, Carlsbad, CA, USA) on the Opticont Real-Time PCR System (Bio-Rad Laboratories Inc., Hercules, CA, USA). The primers used for Bfl-1/A1 (NM_004049) were 5 0 -GCT GGG AAA ATG GCT TTG TA-3 0 and 5 0 -TGG CAA TCG TTT CCA TAT CA-3 0 and for GAPDH (NM_002046) were 5 0 -CGA CCA CTT TGT CAA GCT CA-3 0 and 5 0 -AGG GGT CTA CAT GGC AAC TG-3 0 . Amplicon size and reaction specificity were confirmed by agarose gel electrophoresis and melting curves. All PCR reactions were run in triplicate. The biological experiment was performed at least three times independently. The raw data were analyzed by subtraction of the background and setting the threshold to receive the threshold cycle (C t ) using Opticon Monitor (Bio-Rad Laboratories Inc., Hercules, CA). Further analysis was performed in Excel. The median was taken from triplicate reactions and normalized by GAPDH (subtraction of the Bfl-1/A1-Ct from the GAPDH-Ct). The fold changes were calculated as inverse log to the base of 2.
Results and discussion
All-trans retinoic acid induces differentiation and cell growth inhibition, but not apoptosis, in leukemia cells
It has been shown that ATRA is a potent differentiation inducer of NB4 and HL-60 cells. 28, 30 Utilizing the NBT reduction ability as a differentiation marker, it was confirmed that ATRA at a pharmacological concentration of 10 À6 M induced both NB4 and HL-60 cell differentiation. Unlike NB4 and HL-60 cells, ATRA treatment did not induce differentiation in ATRAdifferentiation resistant R4 and HL-60/Res cells. The NBTpositive cells in NB4, R4, HL-60 and HL-60/Res cells after treatment with 1 mM ATRA for 4 days are 45.6, 1.3, 56.2 and 1.8%, respectively. The cell growth was inhibited without loss of viability after 4 days of 1 mM ATRA treatment. All-trans retinoic acid inhibited growth of NB4, R4, HL-60 and HL-60/Res cells at a rate of 17.6, 21.3, 47.6 and 25.3%, respectively. Although modest apoptosis induction has been reported in NB4 cells after 5-6 days of ATRA treatment, 35 apoptotic cells were not detected in any of the four cell lines after 4 days of treatment with 1 mM ATRA All-trans retinoic acid pretreatment, but not simultaneous treatment, decreases doxorubicin-induced apoptosis in NB4 and HL-60 cells
Currently ATRA with an anthracycline is being used in the firstline treatment of newly diagnosed t(15;17) APL patients because this regimen was found to induce longer remissions than either agent alone. 5, 36 However, although there was no difference in remission rates between simultaneous treatment with ATRA and chemotherapy or ATRA treatment followed by chemotherapy, the duration of remission was longer with simultaneous treatment. 37, 38 The combined effect of both agents given sequentially or simultaneously has not been tested in vitro in APL cells. Doxorubicin is an anthracycline cytotoxic agent. 39 The combined effect of ATRA with Dox in terms of differentiation and apoptosis was studied in the four leukemia cell lines. Apoptosis was first measured according to morphological changes. As shown in Figure 1a , Dox-induced apoptosis in all of the four leukemia cell lines with greater response in NB4, R4 and HL-60/Res cells than that in HL-60 cells. However, when these cells were pretreated with ATRA for 3 days, Dox-induced apoptosis was decreased in NB4 cells and HL-60 cells, but not À6 mM ATRA, 0.01 or 0.05 mM Dox alone or in combination as indicated for 3 days. Differentiation was determined by nitroblue tetrazolium (NBT) reduction as described in Material and methods. The data are the mean of three independent experiments7s.d. (Figure 1a) . Interestingly, a slight increase of Dox-induced apoptosis was observed in R4 and HL-60/Res cells (Figure 1a ). To further confirm the different response of APL cells to Dox-induced apoptosis in ATRA-pretreated APL cells, apoptotic cells were quantitatively measured in NB4 cells using FACS after staining with annexin V-FITC. As shown in Figure 1b , the Dox-induced apoptosis was attenuated in ATRApretreated NB4 cells (Figure 1b) . When ATRA and Dox given simultaneously, ATRA 1 mM did not significantly influence Doxinduced apoptosis in NB4 cells and HL-60 cells after 24 h treatment at a concentration of 0.5 mM (Figure 1c and data not shown). These data suggest that an antiapoptotic program is initiated during the ATRA-induced differentiation process which attenuates Dox-induced apoptosis. As ATRA functions by inducing cell differentiation, the effect of Dox at non-toxic low concentrations (0.01 and 0.05 mM) on ATRA-induced cell differentiation was examined. As shown in Figure 1d , Dox by itself did not induce significant cell differentiation as measured by NBT reduction. Doxorubicin slightly enhanced ATRAinduced cell differentiation in NB4 cells (Figure 1d ), but Dox did not induce cell differentiation nor overcome ATRA resistance in R4 cells (data not shown). These data suggest that NB4 and HL-60 cells undergoing differentiation become less sensitive to Dox-induced apoptosis.
Bfl-1/A1 attenuates apoptosis in APL cells
All-trans retinoic acid pretreatment inhibits paclitaxel and As 2 O 3 -induced apoptosis in differentiated NB4 and HL-60 cells As 2 O 3 induces clinical remission by both differentiation and/or apoptosis induction in APL patients in relapse following ATRA therapy. 7, 40 Paclitaxel, a derivative of taxol, which has been used to treat solid tumors, has been studied in clinical trials of therapy for acute myeloid leukemia. 41 The effect of these two agents on differentiation and apoptosis induction in APL cells was studied. Previously, it was shown that As 2 O 3 induced Figure 2 DNA fragmentation and apoptosis induced by arsenic trioxide (As 2 O 3 ) or paclitaxel treatment in NB4 and R4 cells pretreated with or without ATRA. NB4 and R4 cells were grown in the presence or absence of 10 À6 mM ATRA for 3 days following As 2 O 3 or paclitaxel treatment at the indicated concentrations for 24 h. DNA fragmentation (a and c) was determined as described in Materials and methods and apoptotic cells (b and d) were determined using FACS after staining with annexin V-FITC.
L Xia et al minimal differentiation of NB4, R4 or HL-60/Res cells at noncytotoxic concentrations below 0.5 mM after 4 days of treatment. 14 Similar to As 2 O 3 , paclitaxel did not induce these cells to undergo differentiation at concentrations below 0.01 mM, which were not cytotoxic (data not shown). Both agents at increased concentrations were potent apoptosis inducers in these cells ( Figure 2) . As reported previously. 13, 31 As 2 O 3 induces apoptosis in both NB4 and R4 cells at concentrations above 1 mM after 24 h treatment based on DNA fragmentation assay and annexin V staining (Figure 2) . However, 5-10 mM As 2 O 3 was required to induce apoptosis in HL-60 and HL-60/Res cells after 24 h treatment (data not shown).
The apoptosis induced by paclitaxel or As 2 O 3 was decreased in NB4 cells, but not in R4 cells, after ATRA pretreatment for 3 days followed by 24 h treatment with As 2 O 3 or paclitaxel ( Figure 2 ). As ATRA treatment inhibits cell growth of both NB4 and R4 cells to a similar extent, these observations support the notion that differentiation induction, not cell growth inhibition, generates an antiapoptotic program that may inhibit As 2 O 3 or paclitaxel-induced apoptosis in ATRA-pretreated APL cells.
Induction of Bfl-1/A1 expression in ATRA-differentiated APL cells correlates with a decrease in sensitivity to apoptosis induction. Antiapoptotic proteins Bcl-2, Mcl-1 and Bcl-X L are modulated during the differentiation induction process and have been shown to inhibit chemotherapeutic agent-induced apoptosis. 18, 19, [42] [43] [44] DNA microarray analyses have shown that several antiapoptotic proteins were induced in differentiated NB4 cells after ATRA treatment. 45, 46 It is possible that these upregulated antiapoptotic proteins contribute to the observed antiapoptotic effect in differentiated NB4 cells. The levels of these antiapoptotic proteins were determined in the four tested cell lines after ATRA treatment for 3 days. As shown in Figure 3a , Bcl-2 protein was significantly decreased by ATRA treatment in both NB4 and HL-60 cells, but not in R4 cells. This is consistent with a previous report that ATRA treatment decreased Bcl-2 protein in NB4, but not in R4 cells. 23 Bcl-2 protein was also decreased by ATRA treatment in HL-60/Res cells even though differentiation was not induced. As Bcl-2 functions as an antiapoptotic protein, ATRA-pretreated NB4, HL-60 and HL-60/Res cells should be more sensitive to chemotherapeutic agent-induced apoptosis. However, only a weakly enhanced effect was observed in HL-60/Res cells after the cells were pretreated with ATRA then treated with Dox ( Figure 1a) . These data indicate that Bcl-2 protein does not mediate sensitivity to apoptosis during the late stage of ATRAinduced NB4 and HL-60 cell differentiation. Other members of the Bcl-2 family might compensate for the loss of Bcl-2 protein and account for the decrease of apoptosis induction. Thus, several other Bcl-2 members have been measured in these four cell lines after ATRA-treatment. Bcl-X L protein was not expressed before or after ATRA treatment. Mcl-1 protein was upregulated after ATRA treatment in both NB4 and R4 cells, but not/weakly in HL-60 and HL-60/Res cells ( Figure 3a) . As Mcl-1 protein has been shown to inhibit apoptosis in a fashion similar to that of Bcl-2 protein, 47, 48 Mcl-1 protein might contribute to the observed apoptosis inhibition in ATRA-treated NB4 cells. However, its strong upregulation by ATRA treatment in R4 cells and weak induction in HL-60 cells suggest that Mcl-1 is not the only factor responsible for inhibition of apoptosis in ATRAtreated NB4 and HL-60 cells. Gene profiles of NB4 cells show that Bfl-1/A1, another antiapoptotic member of the Bcl-2 family, is strongly induced after ATRA treatment. 45 As a reliable antibody is not available for detecting Bfl-1/A1 protein, Bfl-1/ A1 mRNA levels were measured by Northern blot analysis. Bfl-1/A1 mRNA was not detected in any of the four tested cell lines.
However, its expression was induced by ATRA treatment in both NB4 and HL-60 cells, but not in R4 and HL-60/Res cells (Figure 3b ). Bfl-1/A1 mRNA induction by ATRA was time dependent, that is, weakly induced in less than 24 h treatment, and strongly induced after 48 h of treatment (Figure 3b ). These results indicate that Bfl-1/A1 mRNA induction correlates with the observed apoptosis inhibition in the four ATRA-pretreated cell lines. Although the mechanism whereby Bfl-1/A1 inhibits apoptosis is unclear, it has been shown that Bfl-1/A1-transfected cells became less sensitive to apoptosis induction by several agents. 27, [49] [50] [51] [52] [53] Thus, Bfl-1/A1 is likely to be a factor that attenuates apoptosis induction by Dox or As 2 O 3 in ATRA differentiated APL cells.
Silencing Bfl-1/A1 partially restores sensitivity of all-trans retinoic acid-pretreated NB4 cells to doxorubicin-induced apoptosis Dicer-siRNA was used to knockdown Bfl-1/A1 mRNA in ATRApretreated NB4 cells to determine its role in mediating apoptosis. The level of Bfl-1/A1 mRNA was quantified by realtime PCR assay. In three independent experiments Bfl-1/A1 mRNA was, consistent with the Northern blot analysis data (Figure 3b ), always upregulated, up to 400-fold. In these experiments GAPDH was used to normalize, because its expression did not change within the experiment (data not shown). Dicer-siRNA decreased the Bfl-1/A1 mRNA level by 80% in ATRA-treated NB4 cells. A representative quantitative RT-PCR result from one experiment is shown in Figure 4a . Dicer-siRNA alone caused minimal cytotoxicity in NB4 cells and ATRA-treated NB4 cells as demonstrated by morphological Bfl-1/A1 attenuates apoptosis in APL cells L Xia et al observation ( Figure 4b ) and more than 85% cell viability as measured by Trypan blue staining. The apoptotic effect of Dox was compared in ATRA-pretreated NB4 cells with or without Dicer-siRNA treatment. Doxorubicin at 0.5 mM induced 79.2% apoptosis in NB4 cells without ATRA pretreatment which was reduced to 16% apoptosis in ATRA-pretreated NB4 cells (Figure 4c ). Dicer-siRNA treatment partially restored sensitivity to Dox-induced apoptosis (65% apoptosis was detected in ATRA-pretreated NB4 cells after Dicer-siRNA treatment following by Dox) (Figure 4c ). These data suggest that Bfl-1/A1, at least in part, involves in the inhibition of Dox-induced apoptosis in ATRA-differentiated APL cells. As it has been found that Bcl-X L and MDR were also involved in chemotherapeutic agent resistance in ATRA-differentiated APL cells, 22, 54 Bfl-1/A1 would be an additional member of an antiapoptotic program developed in ATRA-differentiated APL cells which might antagonize cell death induced by chemotherapeutic agents.
In summary, there is attenuation of apoptosis induced by chemotherapeutic agents in ATRA pretreated differentiating acute myeloid leukemia cells. During the ATRA-induced differentiation process, Bfl-1/A1 mRNA is significantly induced in ATRA-differentiation responsive, but not in ATRA-differentiation resistant, leukemia cells. The upregulated Bfl-1/A1 mRNA expression correlates with the blockade of apoptosis induced by Dox and As 2 O 3 . Knocked down of Bfl-1/A1 mRNA using siRNA in differentiated APL cells partially restores cell sensitivity to Dox-induced apoptosis. Bfl-1/A1 mRNA induction by ATRA is time dependent and Dox-induced apoptosis is not blocked when given simultaneously with ATRA ( Figure 1c) . These data support the simultaneous use of ATRA and Dox in the treatment of APL and in other protocols using combination cytotoxicdifferentiation therapy. 55 Similarly, it has been shown that simultaneous use of ATRA and As 2 O 3 in treating de novo APL has a clinical benefit by inducing a more profound response Figure 4 Knocked down of Bfl-1/A1 mRNA using small interfering RNA (siRNA) partially restores NB4 cell sensitivity to doxorubicin (Dox)-induced apoptosis. (a) RT-PCR amplification curve from one representative experiment. The C t value is the cycle number at a certain threshold. (The lower the C t value the higher the concentration of the template is, which relates directly to the Bfl-1/A1 mRNA.) C, NB4 cells without treatment; C þ siRNA, NB4 cells treated with Dicer-siRNA for 2 days; ATRA, NB4 cells treated with 1 mM ATRA for 3 days; ATRA þ siRNA, NB4 cells treated with 1 mM ATRA for 3 days following Dicer-siRNA treatment for 2 days. The C t values were ATRA: 26.5, ATRA þ siRNA: 29.5, C: 30.5 and C þ siRNA: 32. (b) Morphology of NB4 cells after treatment by Dicer-siRNA. NB4 cells pretreated with or without ATRA for 3 days, then with or without Dicer-siRNA treatment for 2 days. (c) Dox-induced apoptosis. NB4 cells, cultured for 3 days in presence or absence of 1 mM ATRA, were treated with or without Dicer-siRNA of Bfl-1/A1 for 2 days followed by 0.5 mM Dox treatment for 24 h. Apoptotic cells were determined using FACS after staining with annexin V-FITC.
L Xia et al in vivo than either drug alone. 9 The simultaneous regimen may be synergistic in vivo due to decreased Bcl-2 level without sufficient time for ATRA to increase Bfl-1/A1 expression (even when chemotherapy is given with 3-days delay in vivo) since the decreased level of Bcl-2 protein occurs earlier than Bfl-1/A1 mRNA induction by ATRA. 14 Our data suggest that the antiapoptotic program initiated during the differentiation process should be taken into consideration when designing combinatorial therapy of differentiation inducers with chemotherapeutic agents.
